Business
Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
-- Duration of oxygen support was significantly shorter for subjects treated with inhaled NO LungFit PRO safely delivered 150 ppm NO in the hospital-- GARDEN
About this update from Beyond Air, Inc.
[{"type":"text","content":"-- Duration of oxygen support was significantly shorter for subjects treated with inhaled NO LungFit PRO safely delivered 150 ppm NO in the hospital-- GARDEN CITY, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced positive data from the LungFit® PRO pilot study of high-concentration inhaled NO in Viral Community-Acquired Pneumonia (VCAP), including COVID-19. Incremental data from the completed pilot study was provided in a poster presentation at IDWeek 2022, held from October 19th to 23rd in Washington, D.C., and the poster is available on the Events page of the Beyond Air website (click here). Initial topline data from the study were included in a presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022) on April 25, 2022. “The analysis of the LungFit PRO study in VCAP patients further demonstrates improved efficacy on multiple parameters in the iNO treatment group compared to standard supportive treatment (SST). This is the fourth study in hospitalized subjects suffering from viral respiratory infections completed by Beyond Air with NO concentrations of 150 ppm or more with all studies having data showing a strong safety profile and statistically significant results on key endpoints. We believe high concentration NO delivery with the LungFit PRO generator and delivery system can be a powerful tool against any type of pneumonia, especially COVID-19, and our company is dedicated to bringing this important therapy to market as soon as possible,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. The multi-center, open-label, randomized clinical trial in Israel enrolled a total of 40 subjects hospitalized for VCAP (COVID-19, n=39; other viruses, n=1). Subjects were randomized in a 1:1 ratio to receive inhalations of 150 ppm NO given intermittently for 40 minutes four times per day for up to seven days in addition to standard supportive treatment (NO + SST) or standard supportive treatment alon...